Searching News Database: ciprofloxacin
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 20 May 2016
Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO(TM)
Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO(TM)
HSMN NewsFeed - 30 Nov 2015
OticPharma Appoints Keith A. Katkin as Chairman of the Board of Directors
OticPharma Appoints Keith A. Katkin as Chairman of the Board of Directors
HSMN NewsFeed - 16 Sep 2014
Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners
Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners
HSMN NewsFeed - 20 May 2014
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
HSMN NewsFeed - 31 Dec 2008
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 24 Mar 2008
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
HSMN NewsFeed - 25 Sep 2007
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
HSMN NewsFeed - 27 Aug 2007
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
HSMN NewsFeed - 10 Jul 2007
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
HSMN NewsFeed - 26 Mar 2007
Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets
Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets
HSMN NewsFeed - 12 Feb 2007
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
HSMN NewsFeed - 16 Jan 2007
Aradigm Receives FDA Orphan Drug Designation for Liposomal Ciprofloxacin for Bronchiectasis
Aradigm Receives FDA Orphan Drug Designation for Liposomal Ciprofloxacin for Bronchiectasis
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 21 Dec 2006
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
HSMN NewsFeed - 18 Dec 2006
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Salix Pharmaceuticals Reports American College of Gastroenterology Update
HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
HSMN NewsFeed - 10 May 2006
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
HSMN NewsFeed - 9 May 2006
Aradigm Receives FDA Orphan Drug Designation of Liposomal Ciprofloxacin for Cystic Fibrosis
Aradigm Receives FDA Orphan Drug Designation of Liposomal Ciprofloxacin for Cystic Fibrosis
Additional items found! 93
Members Archive contains
93 additional stories matching:
ciprofloxacin
(Password required)
ciprofloxacin
(Password required)